Caseware UK (AP4) 2023.0.135 2023.0.135 false12023-01-011falseMedical researchtrue 13798071 2023-01-01 2023-12-31 13798071 2021-12-13 2022-12-31 13798071 2023-12-31 13798071 2022-12-31 13798071 c:Director4 2023-01-01 2023-12-31 13798071 d:CurrentFinancialInstruments 2023-12-31 13798071 d:CurrentFinancialInstruments 2022-12-31 13798071 d:CurrentFinancialInstruments d:WithinOneYear 2023-12-31 13798071 d:CurrentFinancialInstruments d:WithinOneYear 2022-12-31 13798071 d:ShareCapital 2023-12-31 13798071 d:ShareCapital 2022-12-31 13798071 d:RetainedEarningsAccumulatedLosses 2023-12-31 13798071 d:RetainedEarningsAccumulatedLosses 2022-12-31 13798071 c:FRS102 2023-01-01 2023-12-31 13798071 c:Audited 2023-01-01 2023-12-31 13798071 c:FullAccounts 2023-01-01 2023-12-31 13798071 c:PrivateLimitedCompanyLtd 2023-01-01 2023-12-31 13798071 c:SmallCompaniesRegimeForAccounts 2023-01-01 2023-12-31 13798071 e:PoundSterling 2023-01-01 2023-12-31 iso4217:GBP xbrli:pure


















Julius Clinical Research UK Ltd
























Directors' report and audited financial statements



For the year ended 31 December 2023



Registered number: 13798071

 
Julius Clinical Research UK Ltd - Registered number:13798071


Statement of financial position
As at 31 December 2023

2023
2023
2022
2022
Note
£
£
£
£

  

Current assets
  

Debtors
 4 
30,735
4,598

Cash at bank and in hand
  
13,756
23,422

  
44,491
28,020

Creditors: amounts falling due within one year
 5 
(36,348)
(24,114)

Net current assets
  
 
 
8,143
 
 
3,906

Total assets less current liabilities
  
8,143
3,906

  

Net assets
  
8,143
3,906


Capital and reserves
  

Share capital
  
1
1

Profit and loss account
  
8,142
3,905

  
8,143
3,906


The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The company has opted not to file the statement of income and retained earnings in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




S Timmerman
Director

Date: 12 September 2024

The notes on pages 2 to 4 form part of these financial statements.

Page 1

 
Julius Clinical Research UK Ltd
 
 

Notes to the financial statements
For the year ended 31 December 2023

1.


General information

The company is a private company limited by shares and incorporated in England and Wales. The registered office
of the company is C/O Buzzacott LLP, 130 Wood Street, London, EC2V 6DL and the principal place of business is Broederplein 41-43, 3703 CD, Zeist, Netherlands. The company registration number is 13798071.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Section 1A of Financial Reporting Standard 102,' the Financial Reporting Standard applicable in the UK and Republic of Ireland' (FRS 102) and the Companies Act 2006.

The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgement in applying the company's accounting policies.

The following principal accounting policies have been applied:

 
2.2

Going concern

The directors have received confirmation from Julius Clinical Research B.V., the ultimate parent company, that it will provide financial support to the company for a period of at least twelve months from the date of approval of these financial statements. The directors have no reason to believe that this support will not be forthcoming. Accordingly, the financial statements have been prepared on a going concern basis.

 
2.3

Turnover

Turnover is recognised to the extent that it is probable that the economic benefits will flow to the company and the turnover can be reliably measured. Turnover is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before turnover is recognised:
Rendering of services
Turnover from a contract to provide services is recognised in the period in which the services are provided in
accordance with the stage of completion of the contract when all of the following conditions are satisfied:
•          the amount of turnover can be measured reliably;
•          it is probable that the company will receive the consideration due under the contract;
•          the stage of completion of the contract at the end of the reporting period can be measured reliably;
            and
•          the costs incurred and the costs to complete the contract can be measured reliably.

Page 2

 
Julius Clinical Research UK Ltd
 

Notes to the financial statements
For the year ended 31 December 2023

2.Accounting policies (continued)

 
2.4

Pensions

Defined contribution pension plan

The company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the company pays fixed contributions into a separate entity. Once the contributions have been paid the company has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Statement of financial position. The assets of the plan are held separately from the company in independently administered funds.

 
2.5

Debtors

Short term debtors are measured at transaction price less any impairment.

 
2.6

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.7

Cash

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on
notice of not more than 24 hours.

  
2.8

Financial instruments

The company only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties and loans to related parties.

 
2.9

Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates income.


3.


Employees

The average monthly number of employees during the year was 1 (2022 - 1).

Page 3

 
Julius Clinical Research UK Ltd
 
 

Notes to the financial statements
For the year ended 31 December 2023

4.


Debtors

2023
2022
£
£

Amounts owed by group undertakings
23,088
1,192

Other debtors
7,647
3,356

Prepayments and accrued income
-
50

30,735
4,598



5.


Creditors: amounts falling due within one year

2023
2022
£
£

Trade creditors
9,573
2,361

Corporation tax
1,193
1,092

Other taxation and social security
2,322
1,641

Other creditors
515
-

Accruals and deferred income
22,745
19,020

36,348
24,114



6.


Contingent liabilities

The company had no contingent liabilities at 31 December 2023 and 31 December 2022.


7.


Capital commitments

The company had no capital commitments at 31 December 2023 and 31 December 2022.




8.


Inclusion in consolidated financial statements

The smallest group undertaking for which financial statements are prepared, which include the company, is Julius Clinical Research B.V. Its registered office is Broederplein 41-43, 3703 CD, Zeist, Netherlands.


9.


Auditors' information

The auditors' report on the financial statements for the year ended 31 December 2023 was unqualified and there were no matters to which the auditor drew attention by way of emphasis.

The audit report was signed on 13 September 2024 by Mark Worsey (Senior statutory auditor) on behalf of Buzzacott LLP.

Page 4